JOHN M WAPLES
Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology HUNTSVILLE, AL NPI 1790765337
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology AL ABBVIE INC. All categories
General Payments — all program years on this page
$11,341.05
- Category: General Payments
- Program years: PY2018–2024
- Record count: 495
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $2,131.64 across 62 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,479.12 | 57 |
| Grant | $500.50 | 1 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $120.00 | 2 |
| Education | $32.02 | 2 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $601.84 | 5 |
| PFIZER INC. | $378.27 | 16 |
| Amgen Inc. | $192.00 | 1 |
| Karyopharm Therapeutics Inc. | $122.76 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $99.87 | 4 |
| E.R. Squibb & Sons, L.L.C. | $94.67 | 5 |
| Janssen Biotech, Inc. | $72.46 | 4 |
| Celgene Corporation | $54.02 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $53.83 | 2 |
| Daiichi Sankyo Inc. | $50.32 | 2 |
| Incyte Corporation | $48.04 | 3 |
| AVEO Pharmaceuticals, Inc. | $43.62 | 2 |
| GENZYME CORPORATION | $38.50 | 1 |
| BARD PERIPHERAL VASCULAR, INC. | $36.58 | 1 |
| Acrotech Biopharma Inc. | $35.85 | 2 |
| Regeneron Healthcare Solutions, Inc. | $31.46 | 2 |
| Gilead Sciences, Inc. | $24.21 | 1 |
| EMD Serono, Inc. | $22.99 | 1 |
| EISAI INC. | $21.99 | 1 |
| BeiGene USA, Inc. | $18.97 | 1 |
| ARRAY BIOPHARMA INC | $18.92 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.37 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $17.83 | 1 |
| Deciphera Pharmaceuticals Inc. | $17.58 | 1 |
| PharmaEssentia USA Corporation | $16.69 | 1 |
By program year
Records — PY2024 (62)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.